國泰航空(00293.HK)2022年淨虧損擴大18.5%至65.48億港元 全年均維持經營正現金流
格隆匯3月8日丨國泰航空(00293.HK)公佈2022年全年業績,期內集團實現收益510.36億港元,同比增長12.0%;國泰航空股東應占虧損65.48億港元,同比擴大18.5%;每股普通股虧損111.3港仙,不派息。
年初集團面對艱難的營運環境,對每月營運現金消耗造成負面影響。然而,隨着香港特別行政區政府於五月一日開始初步調整旅遊限制及檢疫要求,集團在2022年上半年已回覆經營正現金流。下半年香港進一步調整限制措施下,集團於2022年下半年以至全年均維持經營正現金流。
集團於2022年12月31日可動用的無限制用途流動資金結餘為272億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.